Janux therapeutics announces pricing of $350.0 million underwritten public offering of common stock and pre-funded warrants

San diego--(business wire)---- $janx--janux therapeutics, inc. (nasdaq: janx) (janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its tumor activated t cell engager (tractr) and tumor activated immunomodulator (tracir) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purchas.
JANX Ratings Summary
JANX Quant Ranking